A new genome-wide association study has identified 41 previously unknown loci associated with Alzheimer disease. However, these data provide limited insight into disease mechanisms or benefits for clinical prediction of Alzheimer disease.
This is a preview of subscription content
Access options
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$59.00
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.

References
Bertram, L. & Tanzi, R. E. Genomic mechanisms in Alzheimer’s disease. Brain Pathol. 30, 966–977 (2020).
Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 51, 404–413 (2019).
Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat. Genet. 53, 1276–1282 (2021).
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).
Escott-Price, V. & Hardy, J. Genome wide association studies for Alzheimer’s disease: bigger is not always better. Brain Commun. https://doi.org/10.1093/braincomms/fcac125 (2022).
Griciuc, A. & Tanzi, R. E. The role of innate immune genes in Alzheimer’s disease. Curr. Opin. Neurol. 34, 228–236 (2021).
Kachuri, L. et al. Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nat. Commun. 11, 6084 (2020).
Lambert, S. A., Abraham, G. & Inouye, M. Towards clinical utility of polygenic risk scores. Hum. Mol. Genet. 28, R133–R142 (2019).
Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219–1224 (2018).
Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 21, 66–77 (2022).
Acknowledgements
Both authors are supported by grants from the Deutsche Forschungsgemeinschaft (DFG), the European Research Council (ERC) and the Cure Alzheimer’s Fund (CAF). C.M.L. is also supported by the Michael J. Fox Foundation for Parkinson’s Research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lill, C.M., Bertram, L. Genome-wide analysis furthers decoding of Alzheimer disease genetics. Nat Rev Neurol (2022). https://doi.org/10.1038/s41582-022-00678-x
Published:
DOI: https://doi.org/10.1038/s41582-022-00678-x